These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 24368010

  • 1. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB, Behrendt FF, Heinzel A, Krohn T, Mottaghy FM, Bauerschlag DO, Verburg FA.
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [Abstract] [Full Text] [Related]

  • 2. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
    Fagotti A, Fanfani F, Rossitto C, Lorusso D, De Gaetano AM, Giordano A, Vizzielli G, Scambia G.
    Oncology; 2008 Mar; 75(3-4):152-8. PubMed ID: 18827492
    [Abstract] [Full Text] [Related]

  • 3. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G, Altini C, Notaristefano A, Merenda N, Rubini D, Ianora AA, Asabella AN.
    Rev Esp Med Nucl Imagen Mol; 2014 Mar; 33(1):22-7. PubMed ID: 23948509
    [Abstract] [Full Text] [Related]

  • 4. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
    Ghosh J, Thulkar S, Kumar R, Malhotra A, Kumar A, Kumar L.
    Natl Med J India; 2013 Mar; 26(6):327-31. PubMed ID: 25073988
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
    Sanli Y, Turkmen C, Bakir B, Iyibozkurt C, Ozel S, Has D, Yilmaz E, Topuz S, Yavuz E, Unal SN, Mudun A.
    Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
    [Abstract] [Full Text] [Related]

  • 6. [Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)].
    Tönnies S, Bauer TT, Misch D, Boch C, Blum T, Bittner RC, Förster GJ, Kollmeier J.
    Pneumologie; 2012 Apr; 66(4):212-7. PubMed ID: 22477481
    [Abstract] [Full Text] [Related]

  • 7. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
    Klumpp B, Schwenzer NF, Gatidis S, Koenigsrainer I, Koenigsrainer A, Beckert S, Mueller M, Claussen CD, Pfannenberg C.
    Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
    [Abstract] [Full Text] [Related]

  • 8. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer.
    Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, Kang SB.
    Eur J Radiol; 2012 Aug; 81(8):e817-22. PubMed ID: 22595504
    [Abstract] [Full Text] [Related]

  • 9. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
    Mertens LS, Mir MC, Scott AM, Lee ST, Fioole-Bruining A, Vegt E, Vogel WV, Manecksha R, Bolton D, Davis ID, Horenblas S, van Rhijn BW, Lawrentschuk N.
    Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
    Guo H, Zhu H, Xi Y, Zhang B, Li L, Huang Y, Zhang J, Fu Z, Yang G, Yuan S, Yu J.
    J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
    [Abstract] [Full Text] [Related]

  • 11. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
    Castellucci P, Perrone AM, Picchio M, Ghi T, Farsad M, Nanni C, Messa C, Meriggiola MC, Pelusi G, Al-Nahhas A, Rubello D, Fazio F, Fanti S.
    Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
    [Abstract] [Full Text] [Related]

  • 13. Comparison of 18F-FDG positron emission tomography/computed tomography and computed tomography in patients with already-treated breast cancer: diagnostic and prognostic implications.
    Evangelista L, Baretta Z, Vinante L, Bezzon E, De Carolis V, Cervino AR, Gregianin M, Ghiotto C, Saladini G, Pomerri F, Muzzio PC.
    Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):375-84. PubMed ID: 23013667
    [Abstract] [Full Text] [Related]

  • 14. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH.
    J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
    [Abstract] [Full Text] [Related]

  • 15. Detection of recurrent colorectal cancer by 18F-FDG PET/CT comparison with contrast enhanced CT scan.
    Chiewvit S, Jiranantanakorn T, Apisarnthanarak P, Kanchaanapiboon P, Hannanthawiwat C, Ubolnuch K, Phongsawat N, Chiewvit P.
    J Med Assoc Thai; 2013 Jun; 96(6):703-8. PubMed ID: 23951828
    [Abstract] [Full Text] [Related]

  • 16. Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT.
    Jiménez-Bonilla JF, Quirce R, Martínez-Rodríguez I, Banzo I, Rubio-Vassallo AS, Del Castillo-Matos R, Ortega-Nava F, Martínez-Amador N, Ibáñez-Bravo S, Carril JM.
    Lung Cancer; 2013 Jul; 81(1):71-6. PubMed ID: 23597930
    [Abstract] [Full Text] [Related]

  • 17. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study.
    Karunanithi S, Sharma P, Kumar A, Gupta DK, Khangembam BC, Ballal S, Kumar R, Kumar R, Bal C.
    Eur J Radiol; 2014 Jan; 83(1):219-25. PubMed ID: 24191944
    [Abstract] [Full Text] [Related]

  • 18. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
    Purandare NC, Pramesh CS, Karimundackal G, Jiwnani S, Agrawal A, Shah S, Kulkarni M, Laskar SG, Rangarajan V.
    Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
    [Abstract] [Full Text] [Related]

  • 19. Role of FDG PET/CT in staging of recurrent ovarian cancer.
    Son H, Khan SM, Rahaman J, Cameron KL, Prasad-Hayes M, Chuang L, Machac J, Heiba S, Kostakoglu L.
    Radiographics; 2011 Aug; 31(2):569-83. PubMed ID: 21415197
    [Abstract] [Full Text] [Related]

  • 20. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve.
    Kruse V, Van de Wiele C, Borms M, Maes A, Pottel H, Sathekge M, Cocquyt V.
    Nuklearmedizin; 2014 Aug 06; 53(4):131-8. PubMed ID: 25100557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.